[ad_1]
San Diego, December 30, 2021 /PRNewswire/ – Law Firm Robbins Geller Rudman & Dodd Law Firm Announced Revance Therapeutics, Inc. (NASDAQ:RVNC) Securities between November 25, 2019 and October 11, 2021, Including (“class hours”) until February 8, 2022, Seeking to be appointed as lead plaintiff Aramic LLC v. Revance Therapeutics, Inc., No. 21-cv-09585 (ND Cal.).Start at December 10, 2021 And assigned to the judge Edward J. Davila, This Revance therapy The class action alleged that Revance Therapeutics and certain executives violated the Securities Exchange Act of 1934.
If you want to be the lead plaintiff Revance therapy Class action, Please click here to provide your information. You can also contact a lawyer JC Sanchez Robbins Geller call 800/449-4900 or send an email to jsanchez@rgrdlaw.com. Lead the plaintiff’s motion Revance therapy The class action must be no later than February 8, 2022.
Case allegations: Revance Therapeutics is a biotechnology company engaged in the development, manufacturing and commercialization of neuromodulators for various cosmetic and therapeutic indications America And international. Revance Therapeutics’ main drug candidate is DaxibotulinumtoxinA for injection (“DAXI”).exist November 2019, Revance Therapeutics issued a press release announcing that it has submitted a Biologics License Application (“BLA”) to the U.S. Food and Drug Administration.
The full story on Benzinga.com
[ad_2]
Source link
